

1 Formulation of an Antidiabetic Herbal Capsule from Isolated
2 Compounds of Ethanolic Extract of Dregea Volubilis and
3 Leptadenia Reticulata

4 Suchitra. D

5 *Received: 15 June 2021 Accepted: 1 July 2021 Published: 15 July 2021*

6

7 **Abstract**

8 The present investigation was aimed to formulate capsule formulations containing isolated
9 compounds from Dregea volubilis and Leptadenia reticulata. In order to obtain anti diabetic
10 formulations with more effective oral hypoglycemic activity, less side effects, increased patient
11 compliance thereby providing multifaceted benefits. DVLR (DV and LR isolated fraction was
12 mixed in 1:1 ratio) capsules were formulated and the study was carried out for its antidiabetic
13 effect of STZ and HFD induced diabetic rats. Preformulation of capsules were observed as
14 angle of repose and bulk density. Finished capsule formulations were evaluated for weight
15 variation, pH, moisture content, disintegration time, in vitro-drug release percentage and in
16 vivo anti diabetic studies. In our study showed empty capsule shell pH was observed as 3.62
17 and moisture content of capsule was found as <5

18

19 **Index terms**— diabetes mellitus, polyphenolic compound, herbal form ulation.

20 **1 Introduction**

21 Medicinal plants are commonly known for their therapeutic value and free from side effects. Keeping this in view,
22 the development of anti diabetic drug from the natural plants being a major thrust area has drawn the attention of
23 the researchers in the field of natural product research because synthetic drugs may cause unwanted side effects.
24 The rational design of novel drugs from traditional medicine offers new prospects in modern healthcare.
25 However, a scientific proof of the anti-diabetic activity of medicinal plants and phytopharmaceuticals with fewer
26 side effects is still lacking. Dregea volubilis and Leptadenia reticulata belongs to the family of Asclepiadaceae
27 which is widely used in Indian traditional medicines. In our previous study, isolated fractions of Dv-1 from ETDV
28 [1] and Lr-1 from ETLR [2] showed promising hypoglycaemic activity and the compound has been confirmed
29 by GC-MS and spectral analysis. The spectral analysis showed that the compounds are polyphenolic in nature.
30 Isolated fractions Dv-1 from ETDV and Lr-1 from ETLR were combined and given a trivial name DVLR which
31 would be used for further studies. In herbal medicine, plant based formulations are used to alleviate the diseases.
32 But the most important challenges faced by these formulations arise because of their lack of complete evaluation.
33 So evaluation is necessary to ensure the quality and the purity of the herbal product. It is very important to
34 establish a system of evaluation for every plant medicine in the market, since the scope for variation in different
35 batches of medicine is enormous. Nutrition is the provision, to cells and organisms, of the materials necessary (in
36 the form of food) to support life. A poor diet can have an injurious impact on health, causing deficiency diseases.
37 Herbal nutritional supplements provide essential nutrients that are not present or present in less amount in diet
38 [3,4]. Hence we formulate the DVLR capsules and the study was carried out for its anti-diabetic effect of STZ
39 induced diabetic rats.

40 2 II.

41 3 Material and Methods

42 4 a) Formulation and Evaluation of Capsules

43 Description and size of capsules are summarized in Table 1. 9el size of capsule purchased from capsule suppliers,
44 Torpac, Fairfield, USA. Capsule especially made for administration of rats.

45 5 b) Preformulation studies

46 Preformulation studies were carried out for the investigation of physicochemical characteristics of a drug substance
47 alone and in combination with excipients. The overall objective of preformulation testing was to generate
48 information which will be useful in developing a stable dosage form.

49 6 i. Angle of Repose

50 A funnel was kept vertically in a stand at a specified height above a paper placed on a horizontal surface. The
51 funnel bottom is closed and 10 g of sample powder (DV and LR isolated fraction was mixed in 1:1 ratio) is filled
52 in funnel. Then funnel was opened to release the powder on the paper to form a smooth conical heap, is found
53 by measuring in different direction. The height of the heap was measured by using scale. The values of angle of
54 repose are calculated by using the following formula: $\tan \theta = h/r$ Where, h is height of the heap and r is radius
55 of the heap.

56 7 ii. Bulk Density

57 A known quantity of powder was poured into the measuring cylinder carefully. The powder was levelled (DV and
58 LR isolated fraction was mixed in 1:1 ratio) without compacting, if necessary and read the unsettled apparent
59 volume, V_o , to the nearest graduated unit. Bulk density was calculated, in gm per ml, by the following formula.
60 Bulk density = Bulk Mass/ Bulk Volume.

61 8 c) Filling of Capsule i. Hand Operated Hard Gelatin Capsule
62 Filling Machine

63 The empty capsules are filled into the loading tray which is placed over the bed. By opening the handle, the
64 bodies of the capsules are locked and caps separated in the loading tray itself, which is then removed by operating
65 the lever. The weighed amount of the drug was mixed with sufficient quantity of excipients to be filled in the
66 capsules and placed in powder tray already kept in position over the bed. The powders are spreaded with the
67 help of a powder spreader so as to fill the bodies of the capsules uniformly to get 200 capsules. The excess of the
68 powder is collected on the platform of the powder tray. Lowered the pin plate and moved it downward so as to
69 press the powder in the bodies. The powder tray is removed and placed the caps on the holding tray in position.
70 The caps are pressed with the help of plate with rubber top and operated the lever to unlock the cap and body
71 of the capsules. The loading tray is removed and the filled capsules are collected in a tray.

72 9 d) Quality Control Parameters for Capsule i. Formulation of
73 Capsule

74 Each formulated capsule contains equivalent to 50 mg of DVL and excipients 30 mg which was priorly grounded
75 which are summarized in Table 2.

76 10 ii. Determination of Moisture Content

77 The test was performed by using KF instrument by Electro Lab. The sample prepared by mixing together the
78 content of four capsules. For low water concentrations (< 0.1 %), the utilization of a titrant with a factor of less
79 than 5 mg/mL recommended. An alternative to the direct volumetric titration are both the external extraction
80 as well as the KF oven technique: during external extraction the sample is dissolved, During analysis by the KF
81 oven technique the water released by heating the sample to an appropriate temperature and then transferred into
82 a volumetric cell [5].

83 11 iii. Determination of pH

84 The pH value of a solution was determined potentiometrically by means of a glass electrode, a reference electrode
85 and a digital pH meter. The pH meter was operated according the manufacturer's instructions. First the
86 apparatus was calibrated using buffer of 4, 9 and 7 pH. One empty capsule was taken and dissolved in 100 ml
87 demineralized water. The electrodes were immersed in the solution and the pH was measured [5].

88 12 iv. Uniformity of Weight

89 Twenty filled capsules were randomly selected and weighed to determine the average weight and were compared
90 with individual capsule weight. The percentage weight variation was calculated [5].

91 13 e) Dissolution Test for Capsule

92 The dissolution test was performed for capsule using USP dissolution apparatus 2 by Electro Lab. The 900 ml
93 of the pH -7.2 phosphate buffer as dissolution medium was introduced into the vessel of the apparatus. For the
94 capsules basket type dissolution apparatus was used. Temperature was maintained at $37.5^{\circ}\text{C} \pm 0.5^{\circ}\text{C}$ [5]. 10 ml
95 of sample was withdrawn at 30, 45, and 60 time interval and replaced by same quantity of fresh buffer solution.
96 The absorbance of samples was measured at 263 nm. The amount of percentage drug release was calculated by
97 using the following formula [6]. Disintegration test was performed with the help of the digital microprocessor
98 based disintegration test apparatus by Electro Lab. One capsule was introduced into each tube and added a disc
99 to each tube. The assembly was suspended in the water in a 1000 ml beaker. The volume of water was such that
100 the wire mesh at its highest point is at least 25 mm below the surface of the water, and at its lower point was
101 at least 25 mm above the bottom of the beaker. The apparatus was operated and maintained the temperature
102 at $37.50 \pm 0.5^{\circ}\text{C}$. The time required to disintegrate all capsules and pass through wire mesh [6].Concentration
103 (mg) = Absorbance /

104 14 g) Anti-diabetic Effect of DVLR on Plasma Glucose

105 Concentration and Lipid Profile in STZ induced Diabetic Rats i. Induction of Diabetes Male Wistar rats each
106 weighing 180-220 g was obtained from Annamalai University at Chidambaram, Tamil Nadu, India. The guidelines
107 of the CPCSEA of the Government of India were followed, and prior permission was granted from the Institutional
108 Animal Ethics Committee (No. 842/CPCSEA). Rodent laboratory chow and water were accessed ad libitum,
109 and rats were maintained on a 12 h light/dark cycle in a temperature regulated room ($20-25^{\circ}\text{C}$) during the
110 experimental procedures. The fasted rats were injected intravenously with 50 mg/kg of STZ along with High
111 Fat Diet (HFD). The HFD was freshly prepared everyday and the method of preparation is described by ??evi,
112 et al., 2004 [7]. Control animals were provided with normal pellet chow (Lipton, India). After 3 days on high
113 fat diet, animals were fasted overnight and diabetes is induced by STZ injection. The STZ was freshly dissolved
114 in citrate buffer (0.01 M, pH 4.5) and kept on ice prior to use. One week after STZ administration, the rats
115 with fasting blood glucose concentrations of over 200 mg/dl were considered to be diabetic and were used in the
116 experiment.

117 15 ii. Effect of DVLR on FBG and the Lipid Profile in Diabetic 118 Rats

119 iii. Assessment of Liver, Kidney and Pancreas Function Blood samples collected from all four groups were allowed
120 to clot at room temperature. Serum was separated by centrifugation at 2500 rpm for 10 minute. The functional
121 state of the liver, kidney and pancreas were assessed by estimating the biochemical parameters of blood serum.
122 After collecting the blood, the animals were sacrificed and their liver, kidney, pancreas was isolated, weighed and
123 preserved in 10% formalin solution for histopathological studies.

124 16 h) Histopathological Studies

125 Histopathology the microscopic study of diseased tissue is an important tool in anatomical pathology, since
126 accurate diagnosis of diabetes and other diseases usually requires histopathological examination of samples [9].
127 The isolated liver, kidney and pancreas were sliced into 5 mm pieces and fixed in neutral formalin solution (10%)
128 for 3 days and washed in running water for about 12 hour. This was followed by dehydration with alcohol of
129 increasing strength (70, 80 and 90%) for 12 hours each. Final dehydration was carried out using absolute alcohol
130 with 3 changes at 12 minute interval. Cleaning was done by using xylol with changes at 15-20 minute interval.
131 After cleaning, the pieces were subjected to paraffin infiltration in automatic tissue processing unit. The pieces
132 were washed in running water to remove formalin completely.

133 17 i) Statistical Analysis

134 Data are expressed as $x \pm \text{SEM}$. Statistical analysis was performed by one-way analysis of variance (ANOVA).
135 The least significant difference test was used for mean comparisons and $P < 0.05$ was considered to be statistically
136 significant.

137 18 III.

138 19 Results

139 20 a) Preformulation studies

140 The latest developments in the fields of formulation science and technology offer new opportunities for filling liquid
141 and semi-solid formulations in hard gelatin capsules. Hence we formulate the DVLR (trivial name) capsules and
142 the study was carried out for its anti-diabetic effect of STZ induced diabetic rats. In our study an angle of repose
143 of sample powder was found to be $30.88^\circ \pm 0.28$ (n=3) and Bulk density of powder sample was found to be 0.6675
144 ± 0.005 (n=3). Empty capsule shell pH was found to be 3.62 and the moisture content of capsule was found to
145 be < 5 % w/w. Filled capsule passed the test for uniformity of weight and DVLR capsules disintegration time
146 was found to be 7 minutes. Percentage release of capsule was observed in Table 3 and Figure ???. From the data
147 dissolution percentage of capsule was found to be 94.17 %.

148 21 b) Effect of DVLR on FBG and the lipid profile in diabetic
149 rats

150 DVLR (50 mg/kg) produced a significant ($P < 0.05$) reduction in FBG as more as metformin in diabetic rats
151 which is summarized in Table 4. Additionally DVLR also caused significant ($P < 0.05$) reduction in the level of
152 triglyceride, cholesterol, LDL and significant ($P < 0.05$) improvement in HDL when compared to normal control
153 which was summarized in Table 4 and shown in Figure 2 and 3. The changes in mean percentage blood glucose
154 in diabetic control group is 64.15% and DVLR, metformin treated groups are 47.62% and 48.41% respectively
155 when compared to normal control. However the percentage rate of treated groups were decreased in compared
156 to those of diabetic control. The changes in mean percentage of total cholesterol in diabetic control group is
157 32.08% and DVLR, metformin treated groups are 4.18% and 22.17% respectively. On the other hand, changes in
158 mean percentage of triglyceride diabetic control group is 30.48% and DVLR, metformin treated groups are 5.15%
159 and 25.35% respectively when compared to those of normal control. The changes in mean percentage of LDL in
160 diabetic control group is 42.09% and DVLR, metformin treated groups are 2.80% and 19.78% respectively. On
161 the other hand, changes in mean percentage of HDL in diabetic control group is 41.21% and DVLR, metformin
162 treated groups are 1.12%, 14.5% respectively when compared to those of normal control.

163 22 c) Histopathological Studies i. Histopathology of Liver

164 In histopathology studies of liver (Figure ??) normal control group showed structure of liver with sheets of
165 hepatocytes separated by sinusoids cartial vein & portal tract appears. Diabetic control group showed the
166 structure of liver with cords of hepatocytes and small area of lyphmatous cells in diabetic control animals.
167 DVLR treated group showed the structure of liver with sheets of hepatocytes separated by sinusoids cartial vein
168 & portal tract appear in normal. Metformin treated group showed structure of liver with cords of hepatocytes.
169 No morphological changes were observed.

170 23 ii. Histopathology of Kidney

171 In histopathology study of kidney (Figure ??), normal control group showed the structure of kidney with normal
172 glomeruli and renal tubules. Diabetic control group showed the structure of kidney with inflammation of renal
173 tubules and glomeruli. DVLR treated group showed the structure of kidney without inflammation of renal tubules
174 and glomeruli. Metformin treated group showed the structure of kidney without inflammation of renal tubules
175 and glomeruli.

176 24 iii. Histopathology of Pancreas

177 In histopathology study of pancreas (Figure ??) normal control group showed the structure of pancreas with the
178 normal numbers and volume of the islets cells. Diabetic control group showed the structure of pancreas with the
179 numbers of islets cells were severely decreased and severely swelled. DVLR treated group showed the structure of
180 pancreas with the numbers of islets cells were moderately decreased and moderately swelled. Metformin treated
181 group showed the structure of pancreas with the numbers of islets cells were slightly decreased and slightly
182 swelled.

183 25 IV.

184 26 Discussion

185 In recent years, interest in using hard gelatin capsules in developing and manufacturing medicines has increased
186 considerably. This is most probably due to rapid advances in dosage forms for hard gelatin capsules. In tandem
187 with this, the structural foundation of a new technology has been developed and realised in the form of efficient
188 process machinery. The formulation of a rapid release hard gelatin capsule can be largely deduced from the
189 physicochemical properties of the drug active. Usually, active compound simply mixed with the excipients and

190 directly filled into the capsules. The costly process of granulation and compression can mostly be avoided. The
191 choice available in terms of capsule type, the range of sizes and the capsule's colour or combination of colours, as
192 well as the possibility of printing directly onto the capsule, means that patient compliance, product recognition
193 and product differentiation can be markedly improved. A range of manual, semi-automatic and automatic filling
194 machines are available for the manufacture of hard gelatin capsules. The latest developments in the fields of
195 formulation science and technology offer new opportunities for filling liquid and semi-solid formulations in hard
196 gelatin capsules. In our study empty capsule shell pH was observed as 3.62. Moisture content of capsule was found
197 to be < 5 % w/w which indicates that there are less chances of microbial growth and capsule will not become soft.
198 Filled capsule passed the test for uniformity of weight, all capsules disintegrated within 7 minutes. Percentage
199 release of dissolution of capsule was found to be 94.17%. Administration of STZ caused rapid destruction of
200 pancreatic cells in rats, which led to impaired glucose stimulated and inhibit insulin release, both of which are
201 marked feature of type II diabetes [10]. The blood glucose-lowering effect of plant extracts is generally depends
202 upon the degree of pancreatic β -cell destruction and useful in moderate streptozotocin induced diabetics [11].
203 Hypertriglyceridemia and hypercholesterolemia are the most common lipid abnormalities in diabetics [12]. In
204 addition, hypertriglyceridemia is a metabolic consequence of hyperinsulinemia, insulin resistance and glucose
205 intolerance [13]. STZ induced diabetic rats also showed the increases in plasma cholesterol and triglyceride
206 concentrations [14], which may contribute to the development and progression of micro vascular and macro
207 vascular complications, including neuropathy, nephropathy, cardiovascular and cerebrovascular diseases. The
208 marked hyperlipidemia (increase in the level of lipid in the body) that characterizes the diabetic state which may
209 be the consequence of the un-inhibited(D D D D)

210 B actions of lipolytic hormones on fat depots [15]. DVLR possesses significant blood glucose lowering and
211 cholesterol lowering activities. For this mechanism DVLR may be acutely stimulates it glucose uptake via
212 activated protein kinase and extracellular signal-related kinase and produced great improvement of the altered
213 lipid profile. It may also participate in the hypolipidemic activity by inactivating hepatic HMG-CoA reductase
214 a key enzyme, in cholesterol synthesis. The improvements in the lipid profile in diabetic animals after treatment
215 with DVLR could be beneficial in preventing diabetic complications, as well as improving lipid metabolism in
diabetic patients. ¹




Figure 1:




Figure 2: Figure 2 :





Figure 3: Figure 3 :Figure 4 :



56

Figure 4: Figure 5 :Figure 6 :

1

Description	Size 9el
Capsule Body Capacity	0.08 ml
Fill Weight (materials with density 1g/ml)	80 mg
External Diameter Maximum	2.65 mm
Length When Locked Maximum	23.2 mm
Weight Empty (Cap & Body) Average	17 mg
Colors Available	Clear & Opaque

Figure 5: Table 1 :

2

Ingredients	Strength (mg)
DV	25
LR	25
Carboxy methyl cellulose (CMC) Q.S	80

Figure 6: Table 2 :

3

	30 minutes %	DVLR	60 minutes %
1	65.72	80.17	93.75
2	66.12	82.27	94.17
3	65.10	81.50	92.97
4	64.98	80.97	94.07
5	65.27	82.15	93.10

Figure 7: Table 3 :

4

Cholesterol (mg/dl) Triglyceride (mg/dl) LDL (mg/dl) HDL (mg/dl)

Figure 8: Table 4 :

216 .1 Acknowledgements

217 The authors express their sincere thanks to the University Grants Commission, New Delhi for financial support
218 to carry out this research UGC-BSR Fellowship Number F.4-1/2006 (BSR)/7-269/20210.

219 [Venkatesan and Smith ()] *A, Effect of active fraction isolated from the leaf extract of Dregea volubilis [Linn.] on*
220 *plasma glucose concentration and lipid profile in streptozotocin-induced diabetic rats*, Anton N Venkatesan ,
221 Smith . 10.1186/2193. 2013. Springer Plus. 2 p. .

222 [Venkatesan and Smith ()] *A, Effect of active fraction isolated from the leaf extract of Leptadenia reticulata*
223 *on plasma glucose concentration and lipid profile in streptozotocin-induced diabetic rats*, *Chinese journal of*
224 *natural medicines*, Anton N Venkatesan , Smith . 10.3724/SP.J.1009.2014.00463. 2014. 12 p. .

225 [Srinivasan ()] ‘Animal models in type II diabetes research: An overview’. Ramarao K Srinivasan . *Indian journal*
226 *of medical research* 2007. 125 p. .

227 [Jianfeng ()] ‘Anti-diabetic effect of burdock *Arctium lappa* (L.) root ethanolic extract on streptozotocin-induced
228 diabetic rats’. Chaopin C L Jianfeng , PengyingZ . 10.5897/AJB11.4107. <https://doi.org/10.5897/AJB11.4107> *African Journal of Biotechnology* 2012. 11 (37) p. .

230 [Millard and Histopathology ()] *Black well scientific publications*, . P R Millard , Histopathology . 1990. London.
231 p. .

232 [Sachdewa and Khemani ()] ‘Ethanol flower extract on blood glucose and lipid profile in streptozotocin induced
233 diabetes in rats’. A Sachdewa , L Khemani . 10.1016/s0378-8741(03)00230-7. *Journal of Ethnopharmacology*
234 2003. 89 p. . (Effect of *Hibiscus rosasinensis* Linn)

235 [Pandey et al. ()] ‘Formulation and evaluation of cedrus deodara Loud extract’ S Pandey , V Devmurari , M
236 Goyani . *Int J Chem Tech Res* 2009. 1 (4) p. .

237 [Government of India, Ministry of Health and Family Welfare Indian Pharmacopoeia ()] ‘Government of India,
238 Ministry of Health and Family Welfare’. *Indian Pharmacopoeia* 2006. II p. .

239 [Khan and Leelamma ()] ‘Hypoglycemic action of Murray Koenigii (curry leaf), *Brassica juncea* (mustard);
240 mechanism of action’ . B A Khan , Abraham A Leelamma . *Indian Journal of Biochemistry and Biophysics*
241 1995. 32 p. .

242 [Devi and Sharma ()] ‘Hypolipidemic effect of different extracts of clerodendron colebrookianum walp in normal
243 and high fat diet fed rats’. R Devi , D Sharma . 10.1016/j.jep.2003.09.022. *Journal of ethnopharmacology*
244 2004. 90 (1) p. .

245 [Gingsberg ()] ‘Lipoprotein metabolism and its relationship to atherosclerosis’ . H Gingsberg . 10.1016/s0025-
246 7125(16)30174-2. *Medicinal and Clinical North America* 1994. 78 p. .

247 [Lax and Simple ()] ‘Method for Administration of Drugs in Solid Form to Fully Conscious Rats’ . E R Lax ,
248 Simple . *Laboratory Animals* 1983. 17 p. .

249 [Henry and Yuan-Li ()] ‘Regulation of plasma triglycerides in insulin resistance and diabetes’ . G N Henry ,
250 Antonio Z Yuan-Li . 10.1016/j.arcmed.2005.01.005. *Archives of Medical Research* 2005. 36 p. .

251 [Mohapatra et al. ()] ‘Standardization of a polyherbal formulation’ P Mohapatra , A Shirwaikara , Aswatharam
252 . *Pharmacognosy magazine* 2008. 4 (13) p. .

253 [Tamizhmani and Ponnusankar ()] ‘Toxicity of using herbs’ T Tamizhmani , Nancy S Ponnusankar . *The indian*
254 *pharmacist* 2003. 14 (2) p. 13.